These findings are highly translational as our clinical work in patients with obstructive sleep apnea demonstrates that intranasal oxytocin administration is beneficial, in part, by increasing cardiac parasympathetic activity [47, 48]. The gene discussed is OXT; the disease is obstructive sleep apnea syndrome.